DPP9 is a novel component of the N-end rule pathway targeting the Tyrosine Kinase Syk

  1. Daniela Justa-Schuch
  2. Maria Silva-Garcia
  3. Esther Pilla
  4. Michael Engelke
  5. Markus Kilisch
  6. Christof Lenz
  7. Ulrike Möller
  8. Fumihiko Nakamura
  9. Henning Urlaub
  10. Ruth Geiss-Friedlander  Is a corresponding author
  1. University Medical Center Goettingen, Germany
  2. MRC Laboratory of Molecular Biology, United Kingdom
  3. Harvard Medical School, United States

Abstract

The aminopeptidase DPP9 removes dipeptides from N-termini of substrates having a proline or alanine in second position. Although linked to several pathways including cell survival and metabolism, the molecular mechanisms underlying these outcomes are poorly understood. We identified a novel interaction of DPP9 with Filamin A, which recruits DPP9 to Syk, a central kinase in B-cell signalling. Syk signalling can be terminated by degradation, requiring the ubiquitin E3 ligase Cbl. We show that DPP9 cleaves Syk to produce a neo N-terminus with serine in position 1. Pulse-chases combined with mutagenesis studies reveal that Ser1 strongly influences Syk stability. Furthermore, DPP9 silencing reduces Cbl interaction with Syk, suggesting that DPP9 processing is a prerequisite for Syk ubiquitination. Consistently, DPP9 inhibition stabilizes Syk, thereby modulating Syk signalling. Taken together, we demonstrate DPP9 as a negative regulator of Syk and conclude that DPP9 is a novel integral aminopeptidase of the N-end rule pathway.

Article and author information

Author details

  1. Daniela Justa-Schuch

    Department of Molecular Biology, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Maria Silva-Garcia

    Department of Molecular Biology, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Esther Pilla

    MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Michael Engelke

    Institute of Cellular and Molecular Immunology, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Markus Kilisch

    Department of Molecular Biology, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Christof Lenz

    Bioanalytics, Institute of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0946-8166
  7. Ulrike Möller

    Department of Molecular Biology, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Fumihiko Nakamura

    Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Henning Urlaub

    Bioanalytics, Institute of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Ruth Geiss-Friedlander

    Department of Molecular Biology, University Medical Center Goettingen, Goettingen, Germany
    For correspondence
    rgeiss@gwdg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1720-3440

Funding

Deutsche Forschungsgemeinschaft (2234/1-2)

  • Ruth Geiss-Friedlander

Heidenreich von Siebold-Programm, Universitaetsmedizin Goettingen

  • Ruth Geiss-Friedlander

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2016, Justa-Schuch et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,851
    views
  • 462
    downloads
  • 38
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Daniela Justa-Schuch
  2. Maria Silva-Garcia
  3. Esther Pilla
  4. Michael Engelke
  5. Markus Kilisch
  6. Christof Lenz
  7. Ulrike Möller
  8. Fumihiko Nakamura
  9. Henning Urlaub
  10. Ruth Geiss-Friedlander
(2016)
DPP9 is a novel component of the N-end rule pathway targeting the Tyrosine Kinase Syk
eLife 5:e16370.
https://doi.org/10.7554/eLife.16370

Share this article

https://doi.org/10.7554/eLife.16370

Further reading

    1. Biochemistry and Chemical Biology
    Aleksandar Bartolome, Julia C Heiby ... Alessandro Ori
    Tools and Resources

    Proteasomes are essential molecular machines responsible for the degradation of proteins in eukaryotic cells. Altered proteasome activity has been linked to neurodegeneration, auto-immune disorders and cancer. Despite the relevance for human disease and drug development, no method currently exists to monitor proteasome composition and interactions in vivo in animal models. To fill this gap, we developed a strategy based on tagging of proteasomes with promiscuous biotin ligases and generated a new mouse model enabling the quantification of proteasome interactions by mass spectrometry. We show that biotin ligases can be incorporated in fully assembled proteasomes without negative impact on their activity. We demonstrate the utility of our method by identifying novel proteasome-interacting proteins, charting interactomes across mouse organs, and showing that proximity-labeling enables the identification of both endogenous and small-molecule-induced proteasome substrates.

    1. Biochemistry and Chemical Biology
    Brennan J Wadsworth, Marina Leiwe ... Randall S Johnson
    Research Article

    Several metabolites have been shown to have independent and at times unexpected biological effects outside of their metabolic pathways. These include succinate, lactate, fumarate, and 2-hydroxyglutarate. 2-Hydroxybutyrate (2HB) is a byproduct of endogenous cysteine synthesis, produced during periods of cellular stress. 2HB rises acutely after exercise; it also rises during infection and is also chronically increased in a number of metabolic disorders. We show here that 2HB inhibits branched-chain aminotransferase enzymes, which in turn triggers a SIRT4-dependent shift in the compartmental abundance of protein ADP-ribosylation. The 2HB-induced decrease in nuclear protein ADP-ribosylation leads to a C/EBPβ-mediated transcriptional response in the branched-chain amino acid degradation pathway. This response to 2HB exposure leads to an improved oxidative capacity in vitro. We found that repeated injection with 2HB can replicate the improvement to oxidative capacity that occurs following exercise training. Together, we show that 2-HB regulates fundamental aspects of skeletal muscle metabolism.